AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Remuneration Information Dec 22, 2023

7612_dirs_2023-12-22_0429d522-8cf2-4cca-9b78-5d3df7fb6ade.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 6822X

Eco Animal Health Group PLC

22 December 2023

22 December 2023

ECO Animal Health Group plc

("ECO" or the "Company")

Deferred Share Option Awards to Executive Directors

ECO Animal Health Group plc announces that on 21 December 2023 deferred nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 44,562 ordinary shares in the Company (representing approximately 0.07 percent of the Company's issued share capital) to two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2023.

Name Position Number of Deferred Share Options
David Hallas Chief Executive Officer 26,985
Chris Wilks Chief Financial Officer 17,577

As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years.

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)
020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

Carlo Spingardi
020 7597 5970
Equity Developments

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

PDMR Notification - ECO DBS Deferred Share Option Awards

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

1.    David Hallas

2.    Chris Wilks

2.            

Reason for the notification

a.            

Position/status

1.    Chief Executive Officer

2.    Chief Financial Officer

b.            

Initial notification

/Amendment 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Eco Animal Health Group Plc

b.           

LEI

2138009XN9DJ3YP70B55

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

GB0032036807 

b.            

Nature of the transaction

Award of nominal cost share options under the Company's DBS.  

c.            

Price(s) and volume(s)

Numbers 1 to 7 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

Price(s) Volume(s)
1.    5p 26,985
2.    5p 17,577

d.            

Aggregated information

Aggregated volume

Price

n/a

e.            

Date of the transaction

21 December 2023

f.            

Place of the transaction

Outside a trading venue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHQFLFLXLLEFBQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.